Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Chief Tech Operations Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 312,744 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 10,340 · Balance 312,744 F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 21,400 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Includes 1,551 shares of Dermira Common Stock acquired by the Reporting Person on November 15, 2019 pursuant to Dermira's Employee Stock Purchase Plan. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2028-05-06 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 140,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 53,333 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Includes 1,551 shares of Dermira Common Stock acquired by the Reporting Person on November 15, 2019 pursuant to Dermira's Employee Stock Purchase Plan.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 10,340 | $6.84 | $70,696.65 |
DisclosureSEC source: 0001193125-26-415531 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,744 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001193125-26-389512 · ownership.xml · derivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-09-08 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389512 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,084 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:04 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 10,366 | $11.16 | $115,637.91 |
DisclosureSEC source: 0001193125-26-383625 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,084 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2026 Filed May 20, 2026 01:52 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 7,002 | $9.01 | $63,072.62 |
DisclosureSEC source: 0001193125-26-231509 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,450 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:50 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 2,187 | $4.00 | $8,748.00 |
DisclosureSEC source: 0001193125-26-057672 · ownership.xml · nonDerivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,452 F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:50 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 117,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057672 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,639 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:20 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,519 | Not disclosed Strike: $13.47 | Not disclosed |
DisclosureSEC source: 0001193125-25-317982 · ownership.xml · derivative · entry 4 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,519 shares Expires 2034-05-01 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F5 · derivative.exercise_date: 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:20 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,119 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317982 · ownership.xml · derivative · entry 3 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,119 shares Expires 2033-05-23 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F4 · derivative.exercise_date: Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:20 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 77,519 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317982 · ownership.xml · derivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,519 shares Expires 2033-04-02 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F3 · derivative.exercise_date: 25% of the shares vested on December 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:20 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 107,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-317982 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,339 F1 · shares: Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 01:39 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 1,899 | $3.25 | $6,171.75 |
DisclosureSEC source: 0001193125-25-285008 · ownership.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,183 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 3,577 | $2.75 | $9,836.75 |
DisclosureSEC source: 0001415889-25-022220 · form4-08182025_080801.xml · nonDerivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,082 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| May 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 1,341 | $2.13 | $2,856.33 |
DisclosureSEC source: 0001415889-25-022220 · form4-08182025_080801.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,659 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006035 · form4-02282025_050206.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 20:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023362 · form4-09132024_040908.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001622 · primarydocument.xml · derivative · entry 5 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerRestricted Stock Unit · Derivative | 53,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-001622 · primarydocument.xml · derivative · entry 4 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,333 shares Expires 2029-06-03 F4 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $7.42 | Not disclosed |
DisclosureSEC source: 0001562180-20-001622 · primarydocument.xml · derivative · entry 3 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2029-02-11 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 140,000 | Not disclosed Strike: $10.14 | Not disclosed |
DisclosureSEC source: 0001562180-20-001622 · primarydocument.xml · derivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2028-05-06 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerCommon Stock | 21,400 | $18.75 | $401,250.00 |
DisclosureSEC source: 0001562180-20-001622 · primarydocument.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · shares: Includes 1,551 shares of Dermira Common Stock acquired by the Reporting Person on November 15, 2019 pursuant to Dermira's Employee Stock Purchase Plan. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| May 17, 2019 Filed May 21, 2019 16:04 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 26,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003028 · primarydocument.xml · derivative · entry 3 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,333 Underlying: Common Stock · 26,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: 1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the "Initial Vest Date") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a "Service Provider" (as defined in the Plan) through the applicable vesting dates. F3 · derivative.expiration_date: 1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the "Initial Vest Date") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a "Service Provider" (as defined in the Plan) through the applicable vesting dates. Read SEC document |
| May 17, 2019 Filed May 21, 2019 16:04 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 9,222 | $10.50 | $96,831.00 |
DisclosureSEC source: 0001562180-19-003028 · primarydocument.xml · nonDerivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,849 Read SEC document |
| May 17, 2019 Filed May 21, 2019 16:04 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 26,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003028 · primarydocument.xml · nonDerivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 19:58 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001001 · primarydocument.xml · derivative · entry 3 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date. F4 · derivative.expiration_date: Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 19:58 UTC | Dermira, Inc. DERM · Entity 11896 | GrantEmployee Stock Options (Right to buy) · Derivative | 65,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001562180-19-001001 · primarydocument.xml · derivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-02-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on February 1, 2019, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 18:16 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002432 · primarydocument.xml · derivative · entry 2 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock F3 · derivative.exercise_date: 1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the "Initial Vest Date") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a "Service Provider" (as defined in the Plan) through the applicable vesting dates. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock Read SEC document |
| May 07, 2018 Filed May 9, 2018 18:16 UTC | Dermira, Inc. DERM · Entity 11896 | GrantStock Options (Right to buy) · Derivative | 140,000 | $10.14 Strike: $10.14 | $1,419,600.00 |
DisclosureSEC source: 0001562180-18-002432 · primarydocument.xml · derivative · entry 1 Horan Christopher · CIK 0001736819 · Chief Technical Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option grant will vest on April 2, 2019 and 1/48th of the total number of shares underlying the option grant will vest monthly thereafter, subject to the award recipient continuing to be a "Service Provider" (as defined in the Plan) through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.